Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Show more
68 TW Alexander Drive, 68 Tw Alexander Dr, Research Triangle Park, NC, 27709, United States
Start AI Chat
Market Cap
307M
52 Wk Range
$4.68 - $9.92
Previous Close
$8.99
Open
$9.07
Volume
205,442
Day Range
$8.85 - $9.15
Enterprise Value
268.6M
Cash
21.95M
Avg Qtr Burn
N/A
Insider Ownership
14.13%
Institutional Own.
53.27%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
PEDMARK™ (sodium thiosulfate) Details Hearing loss | Approved Quarterly sales |